PLASMA SOLUBLE INTERLEUKIN-2 RECEPTOR LEVELS IN PATIENTS WITH MALIGNANT-LYMPHOMA ARE CORRELATED WITH DISEASE-ACTIVITY BUT NOT CELLULAR IMMUNOSUPPRESSION

被引：10

作者：

HAMON, MD

UNAL, E

MACDONALD, I

SHAMIM, F

BOESEN, E

PRENTICE, HG

机构：

[1] Departments of Haematology and Clinical, The Royal Free Hospital and School of Medicine, London

[2] Department of Oncology, The Royal Free Hospital and School of Medicine, London

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 10卷 / 1-2期

关键词：

SOLUBLE INTERLEUKIN-2 RECEPTOR (SIL2R); INTERLEUKIN-2 (IL2); IN-VITRO CYTOTOXICITY; MALIGNANT LYMPHOMA (ML);

D O I：

10.3109/10428199309147363

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Studies of peripheral blood lymphocytes (PBL) and plasma from patients with malignant lymphoma [Hodgkin's disease (HD) and non Hodgkin's lymphoma (NHL)] show that plasma soluble interleukin 2 receptor (sIL2R) levels are closely linked with disease status {normal volunteers (n = 15) 402 +/- 158 u/ml; patients with Hodgkin's disease in remission (n = 4) 525 +/- 195 u/ml or with active disease (n = 11) 3026 +/- 1602 u/ml (p < 0.001); patients with non Hodgkin's lymphoma in remission (n = 6) 462 +/- 202 u/ml, active disease (n = 15) 2713 +/- 1755 u/ml, (p < 0.001)) but no correlation between sIL2R and the inhibition of interleukin 2 (IL2) generated cytotoxicity for the cell line K562. In only 1 of 15 patient plasma samples studied was there a dose dependent inhibition of IL2 generated cell killing. In a further patient, IL2 generated K562 killing was inhibited at all doses (500-3000 brmp units/ml); treatment of this plasma with anti-Interleukin 4 (alphaIL4) had no effect on the potent inhibitory activity of the plasma. Plasma sIL2R levels were markedly elevated in patients receiving IL2 in vivo (pre treatment 520 +/- 170 iu/ml, during treatment 5578 +/- 2564 iu/ml, p = 0.05). The aetiology of immunosuppression in patients with lymphoma appears to be multi-factorial; although sIL2R correlates with disease activity it does not appear to directly mediate immunosuppression in most patients with malignant lymphoma.

引用

页码：111 / 115

页数：5

共 13 条

[1]

Trinchieri G., Matsumoto-Kobayashi M., Clark S.G., Seehra J., London L., Perussia B., Response of resting human peripheral blood natural killer cells to interleukin 2, J. Exp. Med, 160, pp. 1147-1169, (1984)

[2]

Greene W.C., The human interleukin 2 receptor: a molecular and biochemical analysis of structure and function, Clin. Res., 35, pp. 439-450, (1987)

[3]

Wagner D.K., Kiwanuka J., Edwards B.K., Rubin L.A., Nelson D.L., Magrath I.T., Soluble interleukin 2 receptor levels in patients with undifTerentiated and lympho-blastic lymphomas: correlation with survival, J. Clin. Oncol., 5, pp. 1262-1274, (1987)

[4]

Pizzolo G., Chilosi M., Vinante F., Et al., Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease, B. J. Cancer, 55, pp. 427-428, (1987)

[5]

Hellman S., JafTe E.S., Devita V.T., Hodgkin's Disease, Cancer: Principles and Practice of Oncology, pp. 1696-1740, (1989)

[6]

Devita V.T., Jaffe E.S., Mauch P., Longo D.L., Lymphocytic Lymphomas, Cancer: Principles and Practice of Oncology, pp. 1741-1798, (1989)

[7]

Fanslow W.C., Clifford K.N., Park L.S., Et al., Regulation of alloreactivity in vivo by IL4 and the soluble IL4 receptor, J. Immunol., 147, pp. 535-540, (1991)

[8]

Kawakami Y., Custer M.C., Rosenberg S.A., Lotze M.T., IL4 regulated IL2 induction of lymphokine-activated killer cell activity from human lymphocytes, J. Immunol., 142, pp. 3452-3461, (1989)

[9]

Spits H., Yssel H., Paliard X., Kastelein R., Figdor C., De Vries J.E., IL4 inhibits IL2 mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed lymphocyte cultures, J. Immunol., 141, pp. 29-36, (1988)

[10]

Paul W.E., Interleukin 4: a prototypic immuno-regulatory lymphokine, Blood, 77, pp. 1859-1870, (1991)

← 1 2 →